Krsnaa Diagnostics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mitesh Dave

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	3.6yrs

Recente managementupdates

Recent updates

CEO

Mitesh Dave

less than a year

Tenure

Mr. Mitesh Dave is Group Chief Executive Officer of Krsnaa Diagnostics Limited from June 1, 2024. Mr. Mitesh Dave has two decades of diverse industry experience. His track record spans FMCG, OTC, Pharmaceu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rajendra Mutha	Executive Chairman	3.6yrs	₹25.90m	24.87% ₹ 7.4b
Pawan Daga	Chief Financial Officer	3.8yrs	₹3.00m	geen gegevens
Sujoy Bose	Company Secretary & Compliance Officer	1.3yrs	₹1.33m	geen gegevens
Yash Mutha	Joint MD	5.8yrs	₹54.40m	0.68% ₹ 203.6m
Mitesh Dave	Group Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Gaurav Sachdev	National Sales Head	no data	geen gegevens	geen gegevens
Dharmendra Madan Lal Sharma	Vice President	no data	₹2.99m	geen gegevens

2.6yrs

Gemiddelde duur

41yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 543328 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rajendra Mutha	Executive Chairman	3.6yrs	₹25.90m	24.87% ₹ 7.4b
Yash Mutha	Joint MD	5.8yrs	₹54.40m	0.68% ₹ 203.6m
Adesh Gupta	Independent Director	2.5yrs	₹1.15m	geen gegevens
Prem Pradeep	Non Executive Director	no data	geen gegevens	geen gegevens
Chhaya Palrecha	Independent Director	no data	₹1.05m	geen gegevens
Chetan Desai	Independent Director	no data	₹1.00m	geen gegevens
Rajiva Verma	Independent Director	no data	₹1.00m	geen gegevens

3.6yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 543328 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Krsnaa Diagnostics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Krsnaa Diagnostics Limited, Annual General Meeting, Sep 21, 2024

Krsnaa Diagnostics Limited Appoints Mitesh Dave as Member of Risk Management Committee

Krsnaa Diagnostics Limited Appoints Prashant Pandurangrao Deshmukh as Chief Executive Officer

Krsnaa Diagnostics Limited, Annual General Meeting, Sep 25, 2023

Krsnaa Diagnostics Limited Announces Appointment of Sujoy Sudipta Bose as Compliance Officer, Effective July 23, 2023

Krsnaa Diagnostics Limited, Annual General Meeting, Sep 27, 2022

Recent updates

Investor sentiment improves as stock rises 20%

Second quarter 2025 earnings: EPS misses analyst expectations

Krsnaa Diagnostics Limited to Report First Half, 2025 Results on Oct 25, 2024

Krsnaa Diagnostics Limited (NSEI:KRSNAA) agreed to acquire 23.53% stake in Apulki Healthcare Private Limited.

Krsnaa Diagnostics Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Upcoming dividend of ₹2.50 per share

Krsnaa Diagnostics Limited to Report Q2, 2025 Results on Nov 14, 2024

Dividend reduced to ₹2.50

Krsnaa Diagnostics Limited, Annual General Meeting, Sep 21, 2024

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Krsnaa Diagnostics Limited Appoints Mitesh Dave as Member of Risk Management Committee

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹17.90 (vs ₹19.78 in FY 2023)

Now 20% undervalued after recent price drop

Krsnaa Diagnostics Limited Appoints Prashant Pandurangrao Deshmukh as Chief Executive Officer

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

New minor risk - Shareholder dilution

Price target decreased by 7.2% to ₹924

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of ₹2.75 per share at 0.4% yield

Price target increased by 7.0% to ₹996

Krsnaa Diagnostics Limited to Report Q3, 2024 Results on Feb 14, 2024

Investor sentiment improves as stock rises 15%

First quarter 2024 earnings released: EPS: ₹4.66 (vs ₹4.53 in 1Q 2023)

Krsnaa Diagnostics Limited, Annual General Meeting, Sep 25, 2023

Krsnaa Diagnostics Limited to Report Q1, 2024 Results on Aug 12, 2023

Krsnaa Diagnostics Limited Announces Appointment of Sujoy Sudipta Bose as Compliance Officer, Effective July 23, 2023

Investor sentiment deteriorates as stock falls 20%

Price target increased by 11% to ₹930

Full year 2023 earnings: EPS exceeds analyst expectations

Krsnaa Diagnostics Limited Recommends Final Dividend for Financial Year 2022-23

Now 22% undervalued

Now 21% undervalued

Investor sentiment improves as stock rises 20%

Third quarter 2023 earnings released: EPS: ₹4.35 (vs ₹5.67 in 3Q 2022)

Price target decreased to ₹885

Now 20% undervalued

Second quarter 2023 earnings released: EPS: ₹5.73 (vs ₹5.67 in 2Q 2022)

Krsnaa Diagnostics Limited to Report Q2, 2023 Results on Nov 14, 2022

Krsnaa Diagnostics Limited to Report Q3, 2023 Results on Feb 14, 2023

Krsnaa Diagnostics Limited, Annual General Meeting, Sep 27, 2022

Krsnaa Diagnostics Limited Proposes Payment of Final Dividend

Krsnaa Diagnostics Limited to Report Q1, 2023 Results on Aug 04, 2022

Krsnaa Diagnostics Limited Approves Re-Constitution of the Committees of the Board of Directors

Krsnaa Diagnostics Limited Announces Director Changes

Krsnaa Diagnostics Limited to Report Q4, 2022 Final Results on May 28, 2022

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd